This week’s episode of “WisBusiness: the Podcast” is with Ayla Annac, co-founder, president and CEO of Madison-based InvivoSciences.
This pre-clinical stage biotech company is developing a method for creating tissue samples from patients’ blood, urine or skin to test treatments for heart failure. By using artificial intelligence to organize patients into various categories based on factors like age, sex and genetic conditions, the company aims to improve precision medicine approaches for treating these patients.
“If the drug is toxic for that specific patient … it will show on their cardiac tissue that has been grown from the patient,” she said. “The drug for the right patient at the right time … can be developed effectively.”